Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Immunocompetent cell functions in Ph+ acute lymphoblastic leukemia patients on prolonged Imatinib maintenance treatment.

Cancer immunology, immunotherapy : CII - 1 Apr 2011

Maggio Roberta, Peragine Nadia, De Propris Maria Stefania, Vitale Antonella, Elia Loredana, Calabrese Elisabetta, Della Starza Irene, Intoppa Stefania, Milani Maria Laura, Guarini Anna, Foà Robin

Abstract excerpt

Imatinib mesylate (Imatinib) is a potent inhibitor of defined tyrosine kinases and is effectively used for the treatment of malignancies characterized by the constitutive activation of these tyrosine kinases, such as Philadelphia chromosome-positive (Ph(+)) leukemias and gastrointestinal stromal...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antigen Presentation
Share to Benzamides

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell Separation

Share to Dendritic Cells

Share to Imatinib Mesylate

Share to Killer Cells, Natural

Share to Piperazines

Share to Precursor Cell Lymphoblastic Leukemia-Lymphoma

Source

Open in PubMed Open full text

Identifiers

PMID: 21240485
DOI: 10.1007/s00262-010-0966-2
PMCID: PMC11029509

Genes

TNF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-21240485-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 11 closest

Immunocompetent cell functions in Ph+ acute lymphoblastic leukemia patients on prolonged Imatinib maintenance treatment.PMID 21240485Read ↗

Imatinib mesylate minimally affects bcr-abl+ and normal monocyte-derived dendritic cells but strongly inhibits T cell expansion despite reciprocal dendritic cell-T cell activation.Semantic proximity Read ↗

Immune function in children under chemotherapy for standard risk acute lymphoblastic leukaemia - a prospective study of 20 paediatric patients.Semantic proximity Read ↗

Assessment of bone marrow lymphocytic status during tyrosine kinase inhibitor therapy and its relation to therapy response in chronic myeloid leukaemia.Semantic proximity Read ↗

Phenotype of NK Cells Determined on the Basis of Selected Immunological Parameters in Children Treated due to Acute Lymphoblastic Leukemia.Semantic proximity Read ↗

Circulating myeloid dendritic cell directly isolated from patients with chronic myelogenous leukemia are functional and carry the bcr-abl translocation.Semantic proximity Read ↗

Abnormal phenotype of bone marrow plasma cells in patients with chronic myeloid leukemia undergoing therapy with Imatinib.Semantic proximity Read ↗

The BCR-ABL inhibitor nilotinib influences phenotype and function of monocyte-derived human dendritic cells.Semantic proximity Read ↗

The usefulness of routine immunological monitoring during the remission phase in acute lymphoblastic leukemias.Semantic proximity Read ↗

Role of P-glycoprotein in evolution of populations of chronic myeloid leukemia cells treated with imatinibSemantic proximity Read ↗

Resistance to Imatinib of Bcr/Abl P190 Lymphoblastic Leukemia CellsSemantic proximity Read ↗

Cytokine modulation of the susceptibility of acute T-lymphoblastic leukemia cell lines to LAK activity.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.